{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:35:15Z","timestamp":1793907315933,"version":"4.8.0"},"reference-count":19,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,10,13]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Treatment with single-agent ibrutinib can increase susceptibility to PCP in chronic lymphocytic leukemia patients. Key components of PCP diagnosis are increased clinical suspicion and adequate sampling with diagnostic bronchoscopy.<\/jats:p>","DOI":"10.1182\/blood-2016-06-722991","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T03:03:32Z","timestamp":1470711812000},"page":"1940-1943","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":157,"title":["Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib"],"prefix":"10.1182","volume":"128","author":[{"given":"Inhye E.","family":"Ahn","sequence":"first","affiliation":[{"name":"Medical Oncology Service, National Cancer Institute, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Jerussi","sequence":"additional","affiliation":[{"name":"Office of Patient Safety and Clinical Quality, Clinical Center, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Farooqui","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancy Section, Hematology Branch, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tian","sequence":"additional","affiliation":[{"name":"Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancy Section, Hematology Branch, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Gea-Banacloche","sequence":"additional","affiliation":[{"name":"Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111908140831700_B1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111908140831700_B2","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia.","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111908140831700_B3","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9747","key":"2019111908140831700_B4","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"2019111908140831700_B5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"19","key":"2019111908140831700_B6","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"2019111908140831700_B7","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-202124","article-title":"Pneumocystis jerovecii pneumonia in a patient with untreated chronic lymphocytic leukaemia: a novel case and postulations concerning the mechanism.","volume-title":"BMJ Case Rep","author":"Kalkanis"},{"issue":"1","key":"2019111908140831700_B8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2009.12.004","article-title":"Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches.","volume":"23","author":"Morrison","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6","key":"2019111908140831700_B9","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood.V82.6.1695.1695","article-title":"Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.","volume":"82","author":"O\u2019Brien","year":"1993","journal-title":"Blood"},{"issue":"26","key":"2019111908140831700_B10","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.","volume":"30","author":"Fischer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111908140831700_B11","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"2019111908140831700_B12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijid.2016.03.018","article-title":"Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients.","volume":"46","author":"Bienvenu","year":"2016","journal-title":"Int J Infect Dis"},{"issue":"6","key":"2019111908140831700_B13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/QCO.0b013e32834cac17","article-title":"Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools.","volume":"24","author":"Reid","year":"2011","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"2019111908140831700_B14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1378\/chest.08-1309","article-title":"Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates.","volume":"135","author":"Azoulay","year":"2009","journal-title":"Chest"},{"issue":"10","key":"2019111908140831700_B15","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3109\/10428194.2010.506569","article-title":"Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy.","volume":"51","author":"Hashimoto","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111908140831700_B16","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s12185-009-0322-5","article-title":"Pneumocystis jiroveci pneumonia as an atypical presentation of X-linked agammaglobulinemia.","volume":"89","author":"Kanegane","year":"2009","journal-title":"Int J Hematol"},{"issue":"1","key":"2019111908140831700_B17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1378\/chest.12-0477","article-title":"Pneumocystis pneumonia in patients treated with rituximab.","volume":"144","author":"Martin-Garrido","year":"2013","journal-title":"Chest"},{"issue":"8","key":"2019111908140831700_B18","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s10875-013-9951-9","article-title":"Clinical, immunological, and molecular characterization of hyper-IgM syndrome due to CD40 deficiency in eleven patients.","volume":"33","author":"Al-Saud","year":"2013","journal-title":"J Clin Immunol"},{"issue":"4","key":"2019111908140831700_B19","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar3400","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.","volume":"13","author":"Chang","year":"2011","journal-title":"Arthritis Res Ther"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/15\/1940\/1395595\/1940.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/15\/1940\/1395595\/1940.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T13:14:18Z","timestamp":1574169258000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/15\/1940\/35491\/Atypical-Pneumocystis-jirovecii-pneumonia-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,13]]},"references-count":19,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2016,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-06-722991","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,13]]}}}